Borucki Davis, Rohrer Baerbel, Tomlinson Stephen
Medical University of South Carolina.
Res Sq. 2024 Feb 23:rs.3.rs-3970621. doi: 10.21203/rs.3.rs-3970621/v1.
Traumatic brain injury (TBI) is associated with the development of visual system disorders. Visual deficits can present with delay and worsen over time, and may be associated with an ongoing neuroinflammatory response that is known to occur after TBI. Complement activation is strongly associated with the neuroinflammatory response after TBI, but whether it contributes to vision loss after TBI is unexplored.
Acute and chronic neuroinflammatory changes within the dorsal lateral geniculate nucleus (dLGN) and retina were investigated subsequent to murine controlled unilateral cortical impact. Neuroinflammatory and histopathological data were interpreted in the context of behavioral and visual function data. To investigate the role of complement, cohorts were treated after TBI with the complement inhibitor, CR2-Crry.
At 3 days after TBI, complement C3 was deposited on retinogeniculate synapses in the dLGN both ipsilateral and contralateral to the lesion, which was reduced in CR2-Crry treated animals. This was associated with microglia morphological changes in both the ipsilateral and contralateral dLGN, with a more amoeboid phenotype in vehicle compared to CR2-Crry treated animals. Microglia in vehicle treated animals also had a greater internalized VGlut2+ synaptic volume after TBI compared to CR2-Crry treated animals. Microglia morphological changes seen acutely persisted for at least 49 days after injury. Complement inhibition also reduced microglial synaptic internalization in the contralateral dLGN and increased the association between VGLUT2 and PSD95 puncta, indicating preservation of intact synapses. Unexpectedly, there were no changes in the thickness of the inner retina, retinal nerve fiber layer or retinal ganglion layer. Pathologies were accompanied by reduced visual acuity at subacute and chronic time points after TBI, with improvement seen in CR2-Crry treated animals.
TBI induces complement activation within the dLGN and promotes microglial activation and synaptic internalization. Complement inhibition after TBI in a clinically relevant paradigm reduces complement activation, maintains a more surveillance-like microglia phenotype, and preserves synaptic density within the dLGN. Together, the data indicate that complement plays a key role in the development of visual deficits after TBI via complement-dependent microglial phagocytosis of synapses within the dLGN.
创伤性脑损伤(TBI)与视觉系统障碍的发生有关。视觉缺陷可能会延迟出现并随时间恶化,并且可能与TBI后已知发生的持续神经炎症反应有关。补体激活与TBI后的神经炎症反应密切相关,但它是否导致TBI后的视力丧失尚未得到研究。
在小鼠可控单侧皮质撞击后,研究背侧外侧膝状体(dLGN)和视网膜内的急性和慢性神经炎症变化。在行为和视觉功能数据的背景下解释神经炎症和组织病理学数据。为了研究补体的作用,在TBI后用补体抑制剂CR2-Crry对动物进行治疗。
在TBI后3天,补体C3沉积在损伤同侧和对侧dLGN的视网膜膝状体突触上,在接受CR2-Crry治疗的动物中这种沉积减少。这与同侧和对侧dLGN中的小胶质细胞形态变化有关,与接受CR2-Crry治疗的动物相比,在给予载体的动物中呈现出更多的阿米巴样表型。与接受CR2-Crry治疗的动物相比,给予载体的动物在TBI后的小胶质细胞内化VGlut2 +突触体积也更大。急性观察到的小胶质细胞形态变化在损伤后至少持续49天。补体抑制还减少了对侧dLGN中的小胶质细胞突触内化,并增加了VGLUT2与PSD95斑点之间的关联,表明完整突触得以保留。出乎意料的是,视网膜内层、视网膜神经纤维层或视网膜神经节层的厚度没有变化。这些病理变化伴随着TBI后亚急性和慢性时间点视力的下降,在接受CR2-Crry治疗的动物中有所改善。
TBI诱导dLGN内的补体激活,并促进小胶质细胞激活和突触内化。在临床相关模型中,TBI后进行补体抑制可减少补体激活,维持更类似监测的小胶质细胞表型,并保留dLGN内的突触密度。总之,数据表明补体通过dLGN内突触的补体依赖性小胶质细胞吞噬作用在TBI后视力缺陷的发展中起关键作用。